This page shows the latest Vytorin news and features for those working in and with pharma, biotech and healthcare.
ezetimibe) and sister product Vytorin (ezetimibe plus simvastatin) - into a blockbuster franchise.
selling Zetia (ezetimibe) and Vytorin (ezetimibe/simvastatin) in this therapeutic area despite a small effect on cardiovascular outcomes.
Merck &Co fail to convince regulator's advisors. Merck &Co has failed to convince an FDA advisory committee that labelling for its cholesterol-lowering drug Vytorin should include a claim of ... The trial started around 10 years ago - shortly after
But Merck has been hit by the on-going erosion to its cardiovascular and cholesterol drugs Zetia (ezetimibe) and Vytorin (ezetimibe/simvastatin).
Overall pharma sales fell 2% on the back of declines for cholesterol drugs Zetia (ezetimibe) and Vytorin (ezetimibe/simvastatin) as well as immunotherapeutic Remicade (infliximab) which is facing biosimilar competition in
under way nine years ago - shortly after Vytorin was first launched onto the market. ... Undeterred, Merck has said it will now file for approval of updated labelling for Vytorin and Zetia based on the results of IMPROVE-IT next year.
More from news
Approximately 4 fully matching, plus 27 partially matching documents found.
The pharma giant’s aim was to acquire the cholesterol inhibitor Vytorin, a product it had been hoping to develop before being been beaten to the finish line by its competitor.
More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.
We’re IGNIFI. An independent creative agency, we help spark and sustain successful brands for some of the biggest names in...